Syngene International Ltd News

Syngene downgrades its revenue guidance by 5% on Librela inventory impact

Syngene trims FY26 revenue guidance by up to 5% as inventory correction for veterinary drug Librela hits profits, even as core research and CDMO business grows

Syngene International falls to over 2-year low as Q3 net profit slumps 89%

Syngene International fell as much as 5.7 per cent to ₹559.10, the lowest level since April 5, 2023, on the National Stock Exchange (NSE)

Stocks to watch, Jan 23: IndiGo, JSW Steel, Bandhan Bk, Mphasis, DLF, BPCL

Stocks to watch today, January 23, 2026: Tanla Platforms, GSPL, Sona BLW, Adani Gas and India Cements are among other top stocks to track today.

Syngene International Q3 net profit plunges 89%, revenue slips 3%

Librela inventory correction and one-time labour code costs weigh on earnings

Biocon arm Syngene eyes late-stage clinical supplies amid regulatory shift

As regulators ease biosimilar trial norms, Syngene International is expanding into late-stage clinical supply production, betting on biologics and peptide manufacturing for growth

Syngene Q2 profit drops 37% as biologics correction offsets growth

Revenue up 2% YoY to Rs 926 crore as research services offset biologics inventory correction; company maintains FY26 guidance

Jefferies upbeat on India CRDMO; initiates Buy on Cohance; upgrades Divi's

Jefferies is optimistic on India's CRDMO sector, given its evolution from quasi-chemical firms into strategic partners for innovators; check more details